A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Hoffmann-La Roche2,907 enrolled

Overview

A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.

Study Type

OBSERVATIONAL

Enrollment

2,907

Conditions

Breast Cancer

Interventions

BevacizumabDRUG

Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

TrastuzumabDRUG

Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

Ado-trastuzumab emtamsineDRUG

Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time Exclusion Criteria: * Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling * Patients not receiving the Roche studied medicinal product, but a biosimilar

Locations (30)

Outcomes

Primary Outcomes

Percentage of Participants with Different Breast Cancer Subtypes at Diagnosis in Latin America

Time frame: Baseline up to 12 months